<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644616</url>
  </required_header>
  <id_info>
    <org_study_id>156-ZOC-1401</org_study_id>
    <nct_id>NCT02644616</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators research the early improvement of fluid retention and mid-term prognosis
      through the administration of tolvaptan for the patient with tricuspid regurgitation and
      right heart failure after left heart valves replacement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of all the subjects'liquid intake and output volume change after a period(10 days) of treatment</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A cumulative urine volume for 72 hours (all subjects)</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography results VS the baseline results(all subjects)</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of right heart failure signs(all subjects)</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of cardiovascular event (all subjects)</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of serious adverse event(all subjects)</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other adverse events(all subjects)</measure>
    <time_frame>2015.01-2017.12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Right Heart Failure</condition>
  <arm_group>
    <arm_group_label>trial group(tolvaptan group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolvaptan+torasemide</intervention_name>
    <description>tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv</description>
    <arm_group_label>trial group(tolvaptan group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo+torasemide</intervention_name>
    <description>placebo 15mg/d po(10 days) +torasemide 20mg/d iv</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with tricuspid regurgitation and right heart failure after left heart valves
             replacement

          2. Patients who takes existing diuretic

          3. The patient is willing to participate in the study

        Exclusion Criteria:

          1. Patients with hypersensitivity to study drug

          2. Anuric patients

          3. Patients with hypernatremia

          4. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to
             become pregnant

          5. Malignant tumor

          6. Patients with serious hepatic disorder or Serious Renal failure

          7. Patients otherwise judged by the investigator or subinvestigator to be inappropriate
             for inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang Yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FangYuan</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Yuan Fang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>tolvaptan</keyword>
  <keyword>safety and efficacy</keyword>
  <keyword>left heart valves replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 8, 2017</submitted>
    <returned>October 26, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

